Treatment of Severe Sepsis: Where Next? Current and Future Treatment Approaches After the Introduction of Drotrecogin Alfa

References

• AbrahamEArcaroliJCarmodyAHMG-1 as a mediator of acute lung inflammationJ Immun20001652950410975801
   PubMed Web of Science ®Google Scholar
• AbrahamEReinhartKOpalSThe OPTIMIST Trial Study GroupEfficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trialJAMA20032902384712851279
   PubMed Web of Science ®Google Scholar
• AbrahamELaterrePFGargRDrotrecogin alfa (activated) for adults with severe sepsis and a low risk of deathNew Engl J Med200535313324116192478
   PubMed Web of Science ®Google Scholar
• AikawaMRabkinESugiyamaSAn HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo and in vitroCirculation20011032768311208689
   PubMed Web of Science ®Google Scholar
• AikawaNFujishimaSEndoSMulticenter prospective study of procalcitonin as an indicator of sepsisJ Infect Chemother200511152915990980
   PubMedGoogle Scholar
• AirdWCVascular bed-specific hemostatsis: role of endothelium in sepsis pathogenesisCrit Care Med200129Suppl 72835
   Web of Science ®Google Scholar
• AlmogYSheferANovackVPrior statin therapy is associated with a decreased rate of severe sepsisCirculation2004110880515289367
   PubMed Web of Science ®Google Scholar
• AnderssonUWangHPalmbladKHigh mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytesJ Exp Med20001925657010952726
   PubMed Web of Science ®Google Scholar
• AngusDCLinde-ZwirbleWTClermontGCost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsisCrit Care Med200331111112544986
   PubMed Web of Science ®Google Scholar
• AngusDCLinde-ZwirbleWTLidickerJEpidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of careCrit Care Med20012913031011445675
   PubMed Web of Science ®Google Scholar
• AnnaneDSebilleVTrocheGA 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropinJAMA200028310384510697064
   PubMed Web of Science ®Google Scholar
• AnnaneDSebilleVCharpentierCEffect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shockJAMA20022888627112186604
   PubMed Web of Science ®Google Scholar
• AnnaneDBriegelJKehDClinical equipoise remains for issues of adrenocorticotropic hormone administration, cortisol testing, and therapeutic use of hydrocortisoneCrit Care Med2003312250112973194
   PubMed Web of Science ®Google Scholar
• ArgenzianoMChoudhriAFOzMCA prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placementCirculation1997969 SupplII–28690
   Web of Science ®Google Scholar
• ArgenzianoMChenJMChoudhriAFManagement of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agentJ Thor Cardiovasc Surg199811697380
   PubMed Web of Science ®Google Scholar
• AssicotMBendrelDCarsinHHigh serum procalcitonin concentrations in patients with sepsis and infectionLancet1993341515188094770
   PubMed Web of Science ®Google Scholar
• BernardGRVincentJLLaterrePFEfficacy and safety of recombinant human activated protein C for severe sepsisN Engl J Med200134469970911236773
   PubMed Web of Science ®Google Scholar
• BernardGRDrotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsisCrit Care Med200331S859312544981
   PubMed Web of Science ®Google Scholar
• BernardGRMaciasWLJoyceDESafety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsisCritical Care200371556312720562
   PubMed Web of Science ®Google Scholar
• BianchiMEBeltrameMFlexing DNA: HMG-box proteins and their partnersAm J Hum Genet198863157379837808
   PubMedGoogle Scholar
• BianchiMEBeltrameMPaonessaGSpecific recognition of cruciform DNA by nuclear protein HMG1Science1989243105692922595
   PubMed Web of Science ®Google Scholar
• BollaertPECharpentierCLevyBReversal of late septic shock with supraphysiologic doses of hydrocortisoneCrit Care Med199826645509559600
   PubMed Web of Science ®Google Scholar
• BonaldiTTalamoFScaffidiPMonocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretionEmbo J20032255516014532127
   PubMed Web of Science ®Google Scholar
• BoneRCBalkRACerraFBAmerican College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsisChest19921011644551303622
   PubMed Web of Science ®Google Scholar
• BourqueCWOlietSHOsmoreceptors in the central nervous systemAnn Rev Phys19975960119
   PubMed Web of Science ®Google Scholar
• BriegelJForstHHallerMStress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, doubleblind, single-center studyCrit Care Med1999277233210321661
   PubMed Web of Science ®Google Scholar
• BrueckmannMHuhleGLangSPrognostic value of plasma n-terminal pro-brain natriuretic peptide in patients with severe sepsisCirculation20051125273416027260
   PubMed Web of Science ®Google Scholar
• ChenGLiJOchaniMBacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNFdependent mechanismsJ Leuk Biol2004769941001
   PubMed Web of Science ®Google Scholar
• Clec'hCFerriereFKaroubiPDiagnostic and prognostic value of procalcitonin in patients with septic shockCrit Care Med2004321166915190968
   PubMed Web of Science ®Google Scholar
• CooperDJRussellJAWalleyKRfor the VASST InvestigatorsVasopressin (VP) and septic shock trial (VASST): innovative features and performanceAm J Resp Crit Care Med2003167A838
   Google Scholar
• CooperMSStewartPMCorticosteroid insufficiency in acutely ill patientsN Engl J Med20033487273412594318
   PubMed Web of Science ®Google Scholar
• CreaseyAAChangACKFeigenLTissue factor pathway inhibitor reduces mortality from Escherichia coli septic shockJ Clin Invest1993912850608514893
   PubMed Web of Science ®Google Scholar
• CreaseyAANew potential therapeutic modalities: Tissue factor pathway inhibitorSepsis2000317382
   Google Scholar
• CroninLCookDJCarletJCorticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literatureCrit Care Med199523143097634816
   PubMed Web of Science ®Google Scholar
• DavidsonBLGeertsWHLensingAWALow-dose heparin for severe sepsisN Engl J Med20023471036712324565
   PubMed Web of Science ®Google Scholar
• DellingerRPCarletJMMasurHSurviving sepsis campaign guidelines for management of severe sepsis and septic shockCrit Care Med2004328587315090974
   PubMed Web of Science ®Google Scholar
• [DHP] American Society of Health-System PharmacistsDear Healthcare Professional letter, Eli Lilly and Co, April 21, 2005 [online]2005 Accessed July 29, 2005. URL: http://www.ashp.org/news/ShowArticle.cfm?id=10698
   Google Scholar
• DolovichLRGinsbergJSDouketisJDA meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolismArch Intern Med2000160181810647756
   PubMed Web of Science ®Google Scholar
• DunserMWMayrAJUlmerHThe effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysisAnesth Analg20019371311429329
   PubMed Web of Science ®Google Scholar
• DunserMWMayrAJUlmerHArginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled studyCirculation200310723131912732600
   PubMed Web of Science ®Google Scholar
• DunzendorferSRothbucherDSchratzbergerPMevalonatedependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatinCirc Res19978196399400376
   PubMed Web of Science ®Google Scholar
• EilertsenKEOsterudBTissue factor: (patho)physiology and cellular biologyBlood Coagul Fibrinolysis2004155213815389118
   PubMed Web of Science ®Google Scholar
• EinckLBustinMThe intracellular distribution and function of the high mobility group chromosomal proteinsExp Cell Res19851562953103881264
   PubMed Web of Science ®Google Scholar
• ElyEWBernardGRVincentJLActivated protein C for severe sepsisN Engl J Med20023471035612324564
   PubMed Web of Science ®Google Scholar
• EsmonCTTaylorFBJrSnowTRInflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein CThromb Haemost19916616051833850
   PubMed Web of Science ®Google Scholar
• EssigMNguyenGPrieD3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteinsCirc Res199883683909758637
   PubMed Web of Science ®Google Scholar
• FalciolaLSpadaFCalogeroSHigh mobility group 1 protein is not stably associated with the chromosomes of somatic cellsJ Cell Biol199713719269105033
   PubMed Web of Science ®Google Scholar
• FiniganJHDudekSMSingletonPAActivated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivationJ Biol Chem2005280172869315710622
   PubMed Web of Science ®Google Scholar
• FiuzaCBustinMTalwarSInflammation-promoting activity of HMGB1 on human microvascular endothelial cellsBlood200310126526012456506
   PubMed Web of Science ®Google Scholar
• GauthierTWScaliaRMuroharaTNitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemiaArtherioscler Thromb Vasc Biol19951516529
   PubMed Web of Science ®Google Scholar
• GoldJCullinaneSChenJVasopressin in the treatment of milrinone-induced hypotension in severe heart failureAm J Card2000a85506810728962
   PubMed Web of Science ®Google Scholar
• GoldJACullinaneSChenJVasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotensionCrit Care Med2000b282495210667533
   PubMed Web of Science ®Google Scholar
• GoodwinGHJonesEWThe isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteinsMethods Cell Biol19771625767886981
   PubMedGoogle Scholar
• GraybielAGlendyRECirculatory effects following the intravenous administration of Pitressin in normal persons and in patients with hypertension and angina pectorisAm Heart J1941214819
   Google Scholar
• HarrisHEAnderssonUHMGB1 is highly conserved throughout evolution and consists of 215 amino acids. The nuclear protein HMG as proinflammatory mediatorEur J Immunology20043415031215162419
   PubMed Web of Science ®Google Scholar
• HolmesCLPatelBMRussellJAPhysiology of vasopressin relevant to management of septic shockChest2001a120989100211555538
   PubMed Web of Science ®Google Scholar
• HolmesCLWalleyKRChittockDRThe effects of vasopressin on hemodynamics and renal function in severe septic shock: a case seriesInt Care Med2001b27141621
   PubMed Web of Science ®Google Scholar
• HolmesCLWalleyKRVasopressin in the ICUCurr Opin Crit Care200410442815616384
   PubMedGoogle Scholar
• HotchkissRSKarlIEThe pathophysiology and treatment of sepsisN Engl J Med20033481385012519925
   PubMed Web of Science ®Google Scholar
• IbrahimEHShermanGWardSThe influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU settingChest20001181465510893372
   PubMed Web of Science ®Google Scholar
• IgnarroLJBugaGMWoodKSEndothelium-derived relaxing factor produced and released from artery and vein is nitric oxideProc Natl Acad Sci U S A198784926592827174
   PubMed Web of Science ®Google Scholar
• KlinzingSSimonMReinhartKHigh-dose vasopressin is not superior to norepinephrine in septic shockCrit Care Med20033126465014605537
   PubMed Web of Science ®Google Scholar
• KotheHDalhoffKRuppJHydroxymethlglutaryl coenzyme a reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniaeCirculation20001011760310769273
   PubMed Web of Science ®Google Scholar
• KreuzerJBaderJJanhLChemotaxis of the monocytic cell line U937: dependence on cholesterol and early mevalonate pathway productsAtherosclerosis19919020391759991
   PubMed Web of Science ®Google Scholar
• KubesPSuzukiMGrangerDNNitric oxide: an endogenous modulator of leukocyte adhesionProc Natl Acad Sci U S A199188465151675786
   PubMed Web of Science ®Google Scholar
• LandryDWLevinHRGallantEMVasopressin pressor hypersensitivity in vasodilatory septic shockCrit Care Med1997a251279829267938
   PubMed Web of Science ®Google Scholar
• LandryDWLevinHRGallantEMVasopressin deficiency contributes to the vasodilation of septic shockCirculation1997b95112259054839
   PubMed Web of Science ®Google Scholar
• LandryDWOliverJAThe pathogenesis of vasodilatory shockN Engl J Med20013455889511529214
   PubMed Web of Science ®Google Scholar
• LangerMRiccardiFPiovellaFUse of anticoagulants in patients with sepsisJAMA2002287448911798358
   PubMed Web of Science ®Google Scholar
• LaszloFALaszloFJrDeWiedDPharmacology and clinical perspectives of vasopressin antagonistsPharm Rev199143731081852013
   PubMed Web of Science ®Google Scholar
• LaufsUFataVLLiaoJKInhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthaseJ Biol Chem19972723172599395516
   PubMed Web of Science ®Google Scholar
• LaufsULa FataVPlutzkyJUpregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitorsCirculation1998971129359537338
   PubMed Web of Science ®Google Scholar
• LeferingRNeugebauerEASteroid controversy in sepsis and septic shock: a meta-analysisCrit Care Med19952312943037600840
   PubMed Web of Science ®Google Scholar
• LeviMten CateHvan der PollTPathogenesis of disseminated intravascular coagulopathy in sepsisJAMA199327097598345649
   PubMed Web of Science ®Google Scholar
• LevyMMFinkMPMarshallJC2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conferenceCrit Care Med2003311250612682500
   PubMed Web of Science ®Google Scholar
• LevyMMMaciasWLRussellJAFailure to improve during first day of therapy is predictive of 28–day mortality in severe sepsisChest2003124Suppl120S
   Google Scholar
• LiJKokkolaRTabibzadehSStructural basis for the proinflammatory cytokine activity of high mobility group box 1Mol Med20039374512765338
   PubMed Web of Science ®Google Scholar
• LiappisAPKanVLRochesterCGThe effect of statins on mortality in patients with bacteremiaClin Infect Dis2001331352711565076
   PubMed Web of Science ®Google Scholar
• MaciasWLYanSBWilliamsMDNew insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)Crit Care20059Suppl 4S384516168074
   PubMed Web of Science ®Google Scholar
• MartinGSManninoDMEatonSMossMThe epidemiology of sepsis in the United States from 1979 through 2000N Engl J Med200334815465412700374
   PubMed Web of Science ®Google Scholar
• MalayMBAshtonRCJrLandryDWLow-dose vasopressin in the treatment of vasodilatory septic shockJ Trauma19994769970310528604
   PubMed Web of Science ®Google Scholar
• MalayMBAshtonJLDahlKHeterogeneity of the vasoconstrictor effect of vasopressin in septic shockCrit Care Med20043213273115187515
   PubMed Web of Science ®Google Scholar
• MatthayMASevere sepsis–a new treatment with both anticoagulant and antiinflammatory propertiesN Engl J Med20013447596211236781
   PubMed Web of Science ®Google Scholar
• MerxMWLiehnEAJanssensUHMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsisCirculation20041092560515123521
   PubMed Web of Science ®Google Scholar
• MerxMWLiehnEAGrafJStatin treatment after onset of sepsis in a murine model improves survivalCirculation20051121172415998696
   PubMed Web of Science ®Google Scholar
• MeszarosKAberleSDedrickRMonocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing proteinBlood1994832516257513203
   PubMed Web of Science ®Google Scholar
• MorrisseyJHMacikBGNeuenschwanderPFCompPCQuantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activationBlood199381734448427965
   PubMed Web of Science ®Google Scholar
• MosnierLOGriffinJHInhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptorBiochem J2003373657012683950
   PubMed Web of Science ®Google Scholar
• NickJAColdrenCDGeraciMWRecombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxisBlood200410438788515339848
   PubMed Web of Science ®Google Scholar
• NiwaSTotsukaTHayashiSInhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocytes cell lineInt J Immunopharmacol199618669759089010
   PubMed Web of Science ®Google Scholar
• NorskPEllegaardPVidebaekRArterial pulse pressure and vasopressin release in humans during lower body negative pressureAm J Phys1993264R102430
   Google Scholar
• OsterudBRapaportSIActivation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulationProc Natl Acad Sci U S A19777452604271951
   PubMed Web of Science ®Google Scholar
• PackardCJInfluence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)Circulation199897144059576423
   PubMed Web of Science ®Google Scholar
• PahanKSheikhFGNamboodiriAMLovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophagesJ Clin Invest1997100267199389730
   PubMed Web of Science ®Google Scholar
• PatelBMChittockDRRussellJABeneficial effects of shortterm vasopressin infusion during severe septic shockAnesth20029657682
   PubMed Web of Science ®Google Scholar
• QuailAWWoodsRLKornerPICardiac and arterial baroreceptor influences in release of vasopressin and renin during hemorrhageAm J Phys1987252H11206
   Google Scholar
• QuartinAAScheinRMKettDHMagnitude and duration of the effect of sepsis on survivalJAMA19972771058639091694
   PubMed Web of Science ®Google Scholar
• RadomskiMWReesDDDutraAS-Nitroso-glutathione inhibits platelet activation in vitro and in vivoBr J Pharmocol19921077459
   PubMed Web of Science ®Google Scholar
• Rangel-FraustoMSPittetDCostiganMThe natural history of the systemic inflammatory response syndrome (SIRS)JAMA1995273117237799491
   PubMed Web of Science ®Google Scholar
• Rendon-MitchellBOchaniMLiJIFN-g induces high mobility group box 1 protein release partly through a TNF-dependent mechanismJ Immun20031703890712646658
   PubMed Web of Science ®Google Scholar
• ReidIASchwartzJMartiniLGanongWFRole of vasopressin in the control of blood pressureFrontiers in Neuroendocrinology1984New YorkRaven Pr17797
   Google Scholar
• RiedemannNCGuoRFWardPANovel strategies for the treatment of sepsisNat Med200395172412724763
   PubMed Web of Science ®Google Scholar
• RikitakeYKawashimaSTakeshitaSAnti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbitsAtherosclerosis2001154879611137086
   PubMed Web of Science ®Google Scholar
• RiversENguyenBHavstadSEarly goal-directed therapy in the treatment of severe sepsis and septic shockN Engl J Med200134513687711794169
   PubMed Web of Science ®Google Scholar
• SakaiMKoboriSMatsumuraTHMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoproteinAthersclerosis1997133519
   PubMed Web of Science ®Google Scholar
• ScaffidiPMisteliTBianchiMERelease of chromatin protein HMGB1 by necrotic cells triggers inflammationNature2002418191512110890
   PubMed Web of Science ®Google Scholar
• SchmidtGBatesBMcCollamJSClinical use of drotrecogin alfa (activated): patients treated in mercury differ from those in prowessCrit Care Med200312SupplA116
   Google Scholar
• SchrierRWBerlTAndersonRJOsmotic and nonosmotic control of vasopressin releaseAm J Phys1979236F32132
   PubMed Web of Science ®Google Scholar
• SchwartzJKeilLCMaselliJRole of vasopressin in blood pressure regulation during adrenal insufficiencyEndo19831122348
   PubMed Web of Science ®Google Scholar
• SharsharTBlanchardAPaillardMCirculating vasopressin levels in septic shockCrit Care Med2003311752812794416
   PubMed Web of Science ®Google Scholar
• SiegelJPAssessing the use of activated protein C in the treatment of severe sepsisN Engl J Med20023471030412324563
   PubMed Web of Science ®Google Scholar
• Sunden-CullbergJNorrby-TeglundARouhiainenAPersistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shockCrit Care Med2005335647315753748
   PubMed Web of Science ®Google Scholar
• SwaabDFNijveldtFPoolCWDistribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleusJ Endo1975674612
   PubMed Web of Science ®Google Scholar
• TakemotoMLiaoJKPleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reducatase inhibitorsArterioscler Thromb Vasc Biol2001211712911701455
   PubMed Web of Science ®Google Scholar
• TaylorFBJrChangARufWLethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibodyCirc Shock199133127342044206
   PubMedGoogle Scholar
• ThijsLGdeBoerJPde GrootMCMCoagulation disorders in septic shockInt Care Med199319Suppl 1S815
   PubMed Web of Science ®Google Scholar
• TreutigerCJMullinsGEJohanssonASMHigh mobility group 1 B-box mediates activation of human endotheliumJ Int Med200325437585
   PubMed Web of Science ®Google Scholar
• TsuneyoshiIYamadaHKakihanaYHemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shockCrit Care Med2001294879311373409
   PubMed Web of Science ®Google Scholar
• TyrellDJHorneAPHolmeKRHeparin in inflammation: potential therapeutic applications beyond anticoagulationAdv Pharm199946151208
   PubMedGoogle Scholar
• UgarteHSilvaEMercanDProcalcitonin used as a marker of infection in the intensive care unitCrit Care Med19992749850410199528
   PubMed Web of Science ®Google Scholar
• UlloaLOchaniMYangHEthyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammationProc Natl Acad Sci U S A20029912351612209006
   PubMed Web of Science ®Google Scholar
• van der PollTImmunotherapy of sepsisLancet Inf Dis2001116574
   PubMedGoogle Scholar
• van DeventerSJHBullerHRten CateJWExperimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic and complement pathwaysBlood199076252062124934
   PubMed Web of Science ®Google Scholar
• van HarenFMRozendaalFWvan der HoevenJGThe effect of vasopressin on gastric perfusion in catecholamines–dependent patients in septic shockChest200312422566014665508
   PubMed Web of Science ®Google Scholar
• VincentJLSunQDuboisMJClinical trials of immunomodulatory therapies in severe sepsis and septic shockClin Inf Dis2003a34108493
   Web of Science ®Google Scholar
• VincentJLSundinDPTrzaskomaBLChange in first day vasopressor use is predictive of outcome in severe sepsis, regardless of steroid useCrit Care Med2003b12SupplA116
   Google Scholar
• VincentJLLevyMMMaciasWLEarly intervention with drotrecogin alfa (activated) improves survival benefitCrit Care Med2003c12SupplA123
   Google Scholar
• WagnerHNJrBraunwaldEThe pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotensionJ Clin Invest19563514121813385340
   PubMed Web of Science ®Google Scholar
• WangHBloomOZhangMHMG-1 as a late mediator of endotoxin lethality in miceScience19992852485110398600
   PubMed Web of Science ®Google Scholar
• WantLBrownJVarkiAHeparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectinsJ Clin Invest20021101273612093896
   PubMed Web of Science ®Google Scholar
• WarrTARaoLVRapaportSIDisseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activityBlood199075148192317559
   PubMed Web of Science ®Google Scholar
• WarrenHSSuffrediniAFEichackerPQRisks and benefits of activated protein C treatment for severe sepsisN Engl J Med200234710273012324562
   PubMed Web of Science ®Google Scholar
• WesselschmidtRLikertKHuangZStructural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparinBlood Coag Fibrin1993471320
   PubMed Web of Science ®Google Scholar
• WeyckerDAkhrasKSEdelsbergJLong-term mortality and medical care charges in patients with severe sepsisCrit Care Med20033123162314501962
   PubMed Web of Science ®Google Scholar
• WheelerAPSteingrubJLinde-ZwirbleWPrompt administration of drotrecogin alfa (activated) is associated with improved survivalCrit Care Med2003a12SupplA120
   Google Scholar
• WheelerAPDoigCWrightTBaseline characteristics and survival of adult severe sepsis patients treated with drotrecogin alfa (activated) in a global, single–arm, open-label trial (ENHANCE)Chest2003b124SupplS91
   Google Scholar
• WitthautRBuschCFraunbergerPplasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin–6 and sepsis-associated left ventricular dysfunctionIntensive Care Med200329169670212915939
   PubMed Web of Science ®Google Scholar
• WoodCEChenHGAcidemia stimulates ACTH, vasopressin and heart rate responses in fetal sheepAm J Phys1989257R3449
   Google Scholar
• YanSBHelterbrandJDHartmanDLLow levels of protein C are associated with poor outcomes in severe sepsisChest20011209152211555529
   PubMed Web of Science ®Google Scholar
• YangHOchaniMLiJReversing established sepsis with antagonists of endogenous HMGB1Proc Natl Acad Sci U S A200410129630114695889
   PubMed Web of Science ®Google Scholar
• ZengWMatterWFYanSBEffect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signalingCrit Care Med200432Suppl 5S302815118535
   PubMed Web of Science ®Google Scholar
• ZeniFFreemanBNatansonCAnti-inflammatory therapies to treat sepsis and septic shock: a reassessment (editorial)Crit Care Med19972510951009233726
   PubMed Web of Science ®Google Scholar